These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

420 related articles for article (PubMed ID: 32857313)

  • 1. Impact of Real-World Data on Market Authorization, Reimbursement Decision & Price Negotiation.
    Pulini AA; Caetano GM; Clautiaux H; Vergeron L; Pitts PJ; Katz G
    Ther Innov Regul Sci; 2021 Jan; 55(1):228-238. PubMed ID: 32857313
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Real-world data for health technology assessment for reimbursement decisions in Asia: current landscape and a way forward.
    Lou J; Kc S; Toh KY; Dabak S; Adler A; Ahn J; Bayani DBS; Chan K; Choiphel D; Chua B; Genuino AJ; Guerrero AM; Kearney B; Lin LW; Liu Y; Nakamura R; Pearce F; Prinja S; Pwu RF; Shafie AA; Sui B; Suwantika A; Teerawattananon Y; Tunis S; Wu HM; Zalcberg J; Zhao K; Isaranuwatchai W; Wee HL
    Int J Technol Assess Health Care; 2020 Oct; 36(5):474-480. PubMed ID: 32928330
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of two assessments of real-world data and real-world evidence for regulatory decision-making.
    Yuan L; Rahman M; Concato J
    Clin Transl Sci; 2024 Jan; 17(1):e13702. PubMed ID: 38093484
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Use of real-world evidence in regulatory decisions for rare diseases in the United States-Current status and future directions.
    Wu J; Wang C; Toh S; Pisa FE; Bauer L
    Pharmacoepidemiol Drug Saf; 2020 Oct; 29(10):1213-1218. PubMed ID: 32003065
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Real-world data: a comprehensive literature review on the barriers, challenges, and opportunities associated with their inclusion in the health technology assessment process.
    Zisis K; Pavi E; Geitona M; Athanasakis K
    J Pharm Pharm Sci; 2024; 27():12302. PubMed ID: 38481726
    [No Abstract]   [Full Text] [Related]  

  • 6. Current Status, Challenges, and Future Perspectives of Real-World Data and Real-World Evidence in Japan.
    Hiramatsu K; Barrett A; Miyata Y;
    Drugs Real World Outcomes; 2021 Dec; 8(4):459-480. PubMed ID: 34148219
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The role of Real-World Data and evidence in oncology medicines approved in EU in 2018-2019.
    Eskola SM; Leufkens HGM; Bate A; De Bruin ML; Gardarsdottir H
    J Cancer Policy; 2023 Jun; 36():100424. PubMed ID: 37116794
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Case for Real-world Evidence in the Future of Clinical Research on Chronic Myeloid Leukemia.
    Webster J; Smith BD
    Clin Ther; 2019 Feb; 41(2):336-349. PubMed ID: 30709609
    [TBL] [Abstract][Full Text] [Related]  

  • 9. What, Where, and How to Collect Real-World Data and Generate Real-World Evidence to Support Drug Reimbursement Decision-Making in Asia: A reflection Into the Past and A Way Forward.
    Kc S; Lin LW; Bayani DBS; Zemlyanska Y; Adler A; Ahn J; Chan K; Choiphel D; Genuino-Marfori AJ; Kearney B; Liu Y; Nakamura R; Pearce F; Prinja S; Pwu RF; Akmal Shafie A; Sui B; Suwantika A; Tunis S; Wu HM; Zalcberg J; Zhao K; Isaranuwatchai W; Teerawattananon Y; Wee HL
    Int J Health Policy Manag; 2023; 12():6858. PubMed ID: 37579427
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Expert survey on real-world data utilization and real-world evidence generation for regulatory decision-making in drug lifecycle in Korea.
    Lee H; Ahn HS; Kwon S; Kang HY; Han E
    Clin Transl Sci; 2024 Apr; 17(4):e13801. PubMed ID: 38629484
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Availability of comparative real-world evidence research in Medicare patients: implications for Centers for Medicare and Medicaid Services drug price negotiations.
    Jaksa A; Arena PJ; Gatto N
    J Comp Eff Res; 2023 Nov; 12(11):e230125. PubMed ID: 37815792
    [No Abstract]   [Full Text] [Related]  

  • 12. A systematic review of real-world evidence (RWE) supportive of new drug and biologic license application approvals in rare diseases.
    Vaghela S; Tanni KA; Banerjee G; Sikirica V
    Orphanet J Rare Dis; 2024 Mar; 19(1):117. PubMed ID: 38475874
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Contribution of Real-World Evidence in European Medicines Agency's Regulatory Decision Making.
    Bakker E; Plueschke K; Jonker CJ; Kurz X; Starokozhko V; Mol PGM
    Clin Pharmacol Ther; 2023 Jan; 113(1):135-151. PubMed ID: 36254408
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Replication of Randomized, Controlled Trials Using Real-World Data: What Could Go Wrong?
    Thompson D
    Value Health; 2021 Jan; 24(1):112-115. PubMed ID: 33431143
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Real-World Data and Real-World Evidence in Healthcare in the United States and Europe Union.
    Zou KH; Berger ML
    Bioengineering (Basel); 2024 Aug; 11(8):. PubMed ID: 39199742
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Use of Real-World Data and Evidence in Drug Development of Medicinal Products Centrally Authorized in Europe in 2018-2019.
    Eskola SM; Leufkens HGM; Bate A; De Bruin ML; Gardarsdottir H
    Clin Pharmacol Ther; 2022 Jan; 111(1):310-320. PubMed ID: 34689334
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Current Landscape and Emerging Applications for Real-World Data in Diagnostics and Clinical Decision Support and its Impact on Regulatory Decision Making.
    Baumfeld Andre E; Carrington N; Siami FS; Hiatt JC; McWilliams C; Hiller C; Surinach A; Zamorano A; Pashos CL; Schulz WL
    Clin Pharmacol Ther; 2022 Dec; 112(6):1172-1182. PubMed ID: 35213741
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Trial designs using real-world data: The changing landscape of the regulatory approval process.
    Baumfeld Andre E; Reynolds R; Caubel P; Azoulay L; Dreyer NA
    Pharmacoepidemiol Drug Saf; 2020 Oct; 29(10):1201-1212. PubMed ID: 31823482
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Integrating Real-World Evidence in the Regulatory Decision-Making Process: A Systematic Analysis of Experiences in the US, EU, and China Using a Logic Model.
    Li M; Chen S; Lai Y; Liang Z; Wang J; Shi J; Lin H; Yao D; Hu H; Ung COL
    Front Med (Lausanne); 2021; 8():669509. PubMed ID: 34136505
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Real world evidence: An Indian perspective.
    Dang A; Vallish BN
    Perspect Clin Res; 2016; 7(4):156-160. PubMed ID: 27843789
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.